FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

연구 용도로만 사용. 전체 공지 →

펩타이드 라이브러리

Adamax

Adamantane-Acetyl Peptide

Fat Loss & Body Composition

Adamax is an experimental adamantane-modified peptide compound that has emerged in the performance enhancement and fat loss research space with extremely limited published scientific literature. The adamantane moiety (a diamond-shaped hydrocarbon cage structure) is attached to a peptide backbone to theoretically enhance blood-brain barrier penetration, metabolic stability, and receptor binding affinity. Very little is known about its specific mechanism of action, target receptors, or pharmacological profile due to the near-absence of peer-reviewed research.

작용 메커니즘

Adamantane-modified peptide designed for enhanced blood-brain barrier penetration and metabolic stability. The adamantane cage structure protects the peptide from enzymatic degradation while improving lipophilicity and cellular uptake for CNS-mediated metabolic effects.

연구 프로토콜

연구 용도만 사용 가능. 의학적 조언은 아닙니다.

Research protocols are not well-established. Limited published data. Vendor descriptions suggest 200-500mcg daily subcutaneously. Experimental compound with insufficient data for reliable protocol design.

연구 노트

Clinical Research Status

Adamax has no published clinical trials, no regulatory filings, and no formal preclinical development program documented in scientific literature or clinical trial registries. It exists primarily in the gray market of research compounds sold for "research purposes only" without human safety or efficacy data. The compound's origins and development pathway are unclear, with no identified pharmaceutical company or academic institution publicly claiming its creation or characterization.

Key Published Findings

Peer-reviewed literature specifically examining Adamax is essentially nonexistent as of current available databases. The adamantane modification strategy is well-established in pharmaceutical chemistry (examples include amantadine, memantine, and adapalene), where the cage structure improves lipophilicity and metabolic resistance. However, the specific peptide to which the adamantane group is attached in "Adamax" and the resulting pharmacological profile have not been characterized in indexed publications.

Safety Profile

No formal toxicology, pharmacokinetics, or safety studies have been published for Adamax, making any safety claims purely speculative. The adamantane moiety itself has established safety data from approved drugs (amantadine, memantine), but the novel peptide conjugate represents an uncharacterized entity with unknown off-target effects. Users are essentially experimenting with a compound of unknown safety margin, unknown metabolites, and unknown organ toxicity potential.

Comparison to Related Compounds

Without clear mechanistic data, meaningful pharmacological comparison to established fat loss peptides (AOD-9604, tesamorelin) or compounds (GW501516, SR9009) is not possible. The adamantane modification approach distinguishes it structurally from unmodified peptides, potentially offering improved oral bioavailability and CNS penetration. It occupies the same gray market space as other poorly characterized "research compounds" where marketing claims far outpace available scientific evidence.

Community Observations

User reports are sparse and inconsistent, with some claiming enhanced fat oxidation and appetite suppression while others report no noticeable effects. The extremely limited user base and absence of standardized dosing protocols make community anecdotes unreliable for drawing conclusions about efficacy or safety. Most experienced peptide researchers and practitioners recommend against using compounds with this little available safety data when better-characterized alternatives exist.

반감기

~Unknown

재조성

Bacteriostatic water (BAC)

보관

건조한 상태

Refrigerate 2-8C.

재조성된 상태

Refrigerate 2-8C. Use within 14 days.

미국 법적 상태

Research chemical (not FDA-approved)

또는 알려진 이름으로

Adamantane-Acetyl Peptide

자주 묻는 질문

Adamax란 무엇인가요?

Adamax is an experimental adamantane-modified peptide compound that has emerged in the performance enhancement and fat loss research space with extremely limited published scientific literature. The adamantane moiety (a diamond-shaped hydrocarbon cage structure) is attached to a peptide backbone to theoretically enhance blood-brain barrier penetration, metabolic stability, and receptor binding affinity. Very little is known about its specific mechanism of action, target receptors, or pharmacological profile due to the near-absence of peer-reviewed research.

Adamax는 어떻게 작용하나요?

Adamantane-modified peptide designed for enhanced blood-brain barrier penetration and metabolic stability. The adamantane cage structure protects the peptide from enzymatic degradation while improving lipophilicity and cellular uptake for CNS-mediated metabolic effects.

Adamax의 미국 규제 현황은 어떤가요?

Research chemical (not FDA-approved)

Adamax의 반감기는 얼마인가요?

~Unknown

Adamax의 다른 이름은 무엇인가요?

Adamantane-Acetyl Peptide

Peptide Contacts는 정보 제공을 위해 연구 기반 요약을 제공합니다. 우리는 공급업체 문서를 호스팅, 배포하거나 지지하지 않습니다. 모든 테스트 보고서, GMP 인증서 및 공급업체 통신은 구매자는 직접 요청하고 확인해야 합니다. 이 플랫폼에서 제공되는 어떠한 정보도 법적, 의학적 또는 전문적인 조언을 대체하지 않습니다. 사용자는 모든 관련 지역법, 주법 및 연방법에 부합하기 위해 공급업체 자격 증명을 검증하고 구매하기 전에 준수해야 합니다. 이 플랫폼의 사용은 이러한 책임을 완전히 지닌 것으로 간주됩니다.

전체 공지사항 읽기